Gilead Sciences (GILD.US) announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.

Gilead Sciences (GILD.US) shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5
Three markets to watch next week (23.10.2026)
Daily Summary: Oil at five-month highs, indices under pressure (23.10.2026)
US Open: Further declines on Wall Street, Brent above 111 USD, AI correction continues (14.10.2026)
Morning Wrap: AI profitability concerns spark market Sell-Off